PCSK9 and cardiovascular disorder: Although the introduction of lipid-lowering therapies, such as 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) inhibitors and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have lowered the risk of cardiovascular disease.